Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Kewaunee Scientific ( (KEQU) ).
Kewaunee Scientific Corporation held its Annual Meeting of Shareholders virtually on August 27, 2025, where it presented its fiscal year 2025 financial review and strategic direction, including the acquisition of NuAire, Inc. The company’s net sales increased from $203.8 million in FY 2024 to $240.5 million in FY 2025, although net earnings attributable to the corporation decreased from $18.8 million to $11.4 million. The acquisition of NuAire, a leading manufacturer of biosafety cabinets, is expected to expand Kewaunee’s market presence in healthcare, biomedical, and vivarium sectors.
The most recent analyst rating on (KEQU) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.
Spark’s Take on KEQU Stock
According to Spark, TipRanks’ AI Analyst, KEQU is a Outperform.
The stock is supported by strong financial performance, particularly in revenue growth and operational efficiency. Reasonable valuation adds to its attractiveness. Technical indicators signal bullish momentum but caution against potential corrections. The absence of earnings call and corporate events data leads to a moderate overall score.
To see Spark’s full report on KEQU stock, click here.
More about Kewaunee Scientific
Kewaunee Scientific Corporation, founded in 1906, provides comprehensive laboratory solutions across various industries including life sciences, education, healthcare, industrial, petrochemical, and government research. The company is known for delivering tailored laboratory environments that support research and development endeavors.
Average Trading Volume: 11,332
Technical Sentiment Signal: Strong Buy
Current Market Cap: $165.1M
See more data about KEQU stock on TipRanks’ Stock Analysis page.